Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Zaucha

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|January 18, 2018
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 studyJohannes Drach, Huiqiang Huang, Olga Samoilova, et al.
Nature Communications|February 22, 2023
Hypothesis-free phenotype prediction within a genetics-first frameworkChang Lu, Jan Zaucha, Rihab Gam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Cancer Research Communications|December 18, 2025
Characterisation of the immunogenomic landscape of ovarian cancer uncovers a distinct subset of endometroid tumours associated with high CST2 expression and a favourable prognosisJames Boyle, Jan Zaucha, Felicia Ng, et al.
The Journal of Infection|November 10, 2021
Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMTMalgorzata Mikulska, Nina Knelange, Laura Ambra Nicolini, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Human Mutation|April 26, 2017
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGIMarco Carraro, Giovanni Minervini, Manuel Giollo, et al.
Human Mutation|July 20, 2019
CAGI SickKids challenges: Assessment of phenotype and variant predictions derived from clinical and genomic data of children with undiagnosed diseasesLaura Kasak, Jesse M Hunter, Rupa Udani, et al.
American Journal of Hematology|March 21, 2026
Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMTYves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, et al.
Human Mutation|May 26, 2017
Matching phenotypes to whole genomes: Lessons learned from four iterations of the personal genome project community challengesBinghuang Cai, Biao Li, Nikki Kiga, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|January 18, 2018
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 studyJohannes Drach, Huiqiang Huang, Olga Samoilova, et al.
Nature Communications|February 22, 2023
Hypothesis-free phenotype prediction within a genetics-first frameworkChang Lu, Jan Zaucha, Rihab Gam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Cancer Research Communications|December 18, 2025
Characterisation of the immunogenomic landscape of ovarian cancer uncovers a distinct subset of endometroid tumours associated with high CST2 expression and a favourable prognosisJames Boyle, Jan Zaucha, Felicia Ng, et al.
The Journal of Infection|November 10, 2021
Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMTMalgorzata Mikulska, Nina Knelange, Laura Ambra Nicolini, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Human Mutation|April 26, 2017
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGIMarco Carraro, Giovanni Minervini, Manuel Giollo, et al.
Human Mutation|July 20, 2019
CAGI SickKids challenges: Assessment of phenotype and variant predictions derived from clinical and genomic data of children with undiagnosed diseasesLaura Kasak, Jesse M Hunter, Rupa Udani, et al.
American Journal of Hematology|March 21, 2026
Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMTYves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, et al.
Human Mutation|May 26, 2017
Matching phenotypes to whole genomes: Lessons learned from four iterations of the personal genome project community challengesBinghuang Cai, Biao Li, Nikki Kiga, et al.
Pageof 4